Preventive Effects of Berberine on Glucocorticoid-Induced Osteoporosis in Rats

Abstract

Glucocorticoids are widely used to treat chronic diseases such as rheumatoid arthritis and asthma. However, long-term glucocorticoid therapy can result in serious side effects, such as osteoporosis. The present study investigated the preventive effects of berberine on glucocorticoid-induced osteoporosis in rats. Male Sprague Dawley rats were treated with vehicle, glucocorticoid, glucocorticoid and berberine, or glucocorticoid and calcium carbonate with vitamin D₃ for 12 weeks. The proximal tibiae of all rats were processed without decalcification for quantitative bone histomorphometry, and femur mechanical testing as well as bone mineral density (BMD) were analyzed. A significant decrease was found in the glucocorticoid-treated group compared with the control group in such indices as biomechanical quality, BMD, trabecular bone volume/total tissue area (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), mineral apposition rate (MAR), bone formation rate/total tissue area (BFR/TV), and bone formation rate/trabecular bone surface (BFR/BS). In addition, significantly increased trabecular separation (Tb.Sp), osteoclast number/trabecular bone volume (Oc.N/BV), and osteoclast surface/trabecular bone surface (Oc.S/BS) were observed in the glucocorticoid-treated group, compared with the control group. Berberine and calcium carbonate with vitamin D₃ prevented the decrease in biomechanical quality, BMD, BV/TV, Tb.N, Tb.Th, MAR, BFR/TV, and BFR/BS, as well as increased Tb.Sp, Oc.N/BV, and Oc.S/BS in glucocorticoid-induced osteoporotic rats. The present results suggest that berberine prevents glucocorticoid-induced osteoporosis by inhibiting bone resorption and improving bone formation.

berberine - osteoporosis - glucocorticoid - osteoclast - osteoblast

References

• 1 Raisz L G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects.  J Clin Invest. 2005;  115 3318-3325
• 2 Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticoid therapy and hip fracture.  Ann Rheum Dis. 1995;  54 49-52
• 3 Reid I R. Steroid-induced osteoporosis.  Osteoporosis Int. 1997;  7 S213-S216
• 4 Adinoff A D, Hollister J R. Steroid-induced fractures and bone loss in patients with asthma.  N Engl J Med. 1983;  309 265-268
• 5 Michel B A, Bloch D A, Fries J F. Predictors of fractures in early rheumatoid arthritis.  J Rheumatol. 1991;  18 804-808
• 6 Schmeller T, Latz-Bruning B, Wink M. Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores.  Phytochemistry. 1997;  44 257-266
• 7 Ivanovska N, Philipov S. Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids.  Int J Immunopharmacol. 1996;  18 553-561
• 8 Hwang J M, Kuo H C, Tseng T H, Liu J Y. Berberine induces apoptosis through a mitochondria/caspase pathway in human hepatoma cells.  Arch Toxicol. 2006;  80 62-73
• 9 Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang J D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.  Nat Med. 2004;  10 1344-1351
• 10 Li H, Miyahara T, Tezuka Y, Namba T, Suzuki T, Dowaki R, Watanabe M, Nemoto N, Tonami S, Seto H, Kadota S. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine.  Biol Pharm Bull. 1999;  22 391-396
• 11 Lee H W, Suh J H, Kim H N, Kim A Y, Park S Y, Shin C S, Choi J Y, Kim J B. Berberine promotes osteoblast differentiation by runx2 activation with p 38 MAPK.  J Bone Miner Res. 2008;  23 1227-1237
• 12 Cui L, Wu T, Liu Y Y, Deng Y F, Ai C M, Chen H. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.  Acta Pharmacol Sin. 2004;  25 678-684
• 13 Dalle Carbonare L, Bertoldo F, Valenti M T, Zenari S, Zanatta M, Sella S, Giannini S, Cascio V L. Histomorphometric analysis of glucocorticoid-induced osteoporosis.  Micron. 2005;  36 645-652
• 14 Woolf A D. An update on glucocorticoid-induced osteoporosis.  Curr Opin Rheumatol. 2007;  19 370-375
• 15 Downey P A, Siegel M I. Bone biology and the clinical implications for osteoporosis.  Phys Ther. 2006;  86 77-91
• 16 Ortoft G, Andreassen T T, Oxlund H. Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid induced osteopenia.  J Bone Miner Res. 1999;  14 710-721
• 17 Goulding A, Gold E. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomised rats and in ovariectomised rats receiving beta-estradiol.  Endocrinology. 1988;  122 482-487
• 18 Jowell P S, Epstein S, Fallon M D, Reinhardt T A, Ismail F. 1, 25dihydroxyvitamin D3 modulates glucocorticoid-induced alterations in serum bone Gla protein and bone histomorphometry.  Endocrinology. 1987;  120 531-536
• 19 Hu J P, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.  Eur J Pharmacol. 2008;  580 70-79
• 20 Lo Cascio V, Kanis J A, Benetton M N, Bertoldo F, Adami S, Poggi G, Zanolin M E. Acute effects of deflazacort and prednisone on rates of mineralization and bone formation.  Calcif Tissue Int. 1995;  56 109-112
• 21 Dalle Carbonare L, Arlot M E, Chavassieux P M, Roux J P, Portero N R, Meunier P J. Comparison of bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.  J Bone Miner Res. 2001;  16 97-103
• 22 Goulding A, Gold E. Effects of dietary sodium chloride loading on parathyroid function, 1,25-dihydroxyvitamin D, calcium balance, and bone metabolism in female rats during chronic prednisolone administration.  Endocrinology. 1986;  119 2148-2154
• 23 Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton.  Endocrinol Rev. 2008;  29 535-559
• 24 Kim W S, Lee Y S, Cha S H, Jeong H W, Choe S S, Lee M R, Oh G T, Park H S, Lee K U, Lane M D, Kim J B. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.  Am J Physiol Endocrinol Metab. 2009;  296 E812-E819
• 25 Lee Y S, Kim W S, Kim K H, Yoon M J, Cho H J, Shen Y, Ye J M, Lee C H, Oh W K, Kim C T, Hohnen-Behrens C, Gosby A, Kraegen E W, James D E, Kim J B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.  Diabetes. 2006;  55 2256-2264
• 26 Xu D, Zhou C, Liu Y, Xu B. Regulative effect of berberine on glucocorticoid-induced dyslipidemia.  Shizhenguoyiguoyao. 2010;  21 1033-1035
• 27 Kulkarni S K, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders.  Phytother Res. 2010;  24 317-324
• 28 Zeng X H, Zeng X J, Li Y Y. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.  Am J Cardiol. 2003;  92 173-176
• 29 Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.  J Clin Endocrinol Metab. 2008;  93 2559-2565
• 30 Kheir M M, Wang Y, Hua L, Hu J, Li L, Lei F, Du L. Acute toxicity of berberine and its correlation with the blood concentration in mice.  Food Chem Toxicol. 2010;  48 1105-1110